PAPNET-Assisted Rescreening of Cervical Smears

Abstract
ALTHOUGH the Papanicolaou (Pap) smear has contributed to a significant decrease in cervical cancer mortality, conventional cytologic examination misses a significant number of premalignant lesions in which diagnostic cells are present on the slide. Among the tools that are available for reducing the false-negative rate are automated rescreening devices that have been approved recently by the Food and Drug Administration.1-4